Furthermore, a novel nanoplatform has been studied targeting tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to further strengthen DR5-induced apoptosis, which provides a promising approach to clinically overcome tumor resistance (30). This evidence concerns the gene TNFRSF10B and neoplasm.